Susquehanna International Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-62,700
| Closed | -$110K | – | 13635 |
|
|
2024
Q3 | $110K | Sell |
62,700
-1,100
| -2% | -$1.53K | ﹤0.01% | 10990 |
|
|
2024
Q2 | $74.6K | Sell |
63,800
-287,000
| -82% | -$718K | ﹤0.01% | 11209 |
|
|
2024
Q1 | $3.17M | Buy |
350,800
+311,700
| +797% | +$3.03M | ﹤0.01% | 4418 |
|
|
2023
Q4 | $425K | Sell |
39,100
-26,100
| -40% | -$196K | ﹤0.01% | 9063 |
|
|
2023
Q3 | $525K | Sell |
65,200
-38,600
| -37% | -$321K | ﹤0.01% | 8115 |
|
|
2023
Q2 | $1.13M | Buy |
103,800
+4,800
| +5% | +$41.1K | ﹤0.01% | 6401 |
|
|
2023
Q1 | $683K | Sell |
99,000
-19,700
| -17% | -$124K | ﹤0.01% | 7787 |
|
|
2022
Q4 | $472K | Buy |
118,700
+41,800
| +54% | +$205K | ﹤0.01% | 8016 |
|
|
2022
Q3 | $511K | Buy |
76,900
+30,300
| +65% | +$187K | ﹤0.01% | 8431 |
|
|
2022
Q2 | $226K | Sell |
46,600
-3,000
| -6% | -$18.2K | ﹤0.01% | 10331 |
|
|
2022
Q1 | $464K | Sell |
49,600
-57,700
| -54% | -$573K | ﹤0.01% | 9183 |
|
|
2021
Q4 | $1.27M | Sell |
107,300
-40,800
| -28% | -$471K | ﹤0.01% | 6626 |
|
|
2021
Q3 | $1.69M | Sell |
148,100
-119,400
| -45% | -$1.64M | ﹤0.01% | 6206 |
|
|
2021
Q2 | $4.8M | Sell |
267,500
-119,000
| -31% | -$1.91M | ﹤0.01% | 4107 |
|
|
2021
Q1 | $5.98M | Buy |
386,500
+42,100
| +12% | +$609K | ﹤0.01% | 3578 |
|
|
2020
Q4 | $4.2M | Buy |
344,400
+91,500
| +36% | +$1.28M | ﹤0.01% | 3715 |
|
|
2020
Q3 | $3.25M | Buy |
252,900
+173,875
| +220% | +$1.5M | ﹤0.01% | 3726 |
|
|
2020
Q2 | $803K | Sell |
79,025
-29,500
| -27% | -$271K | ﹤0.01% | 6392 |
|
|
2020
Q1 | $881K | Buy |
108,525
+18,350
| +20% | +$159K | ﹤0.01% | 5692 |
|
|
2019
Q4 | $779K | Buy |
90,175
+69,800
| +343% | +$392K | ﹤0.01% | 6021 |
|
|
2019
Q3 | $126K | Sell |
20,375
-162,600
| -89% | -$1.31M | ﹤0.01% | 9434 |
|
|
2019
Q2 | $3.04M | Buy |
182,975
+96,700
| +112% | +$1.68M | ﹤0.01% | 3426 |
|
|
2019
Q1 | $1.44M | Buy |
86,275
+70,700
| +454% | +$1.02M | ﹤0.01% | 4299 |
|
|
2018
Q4 | $179K | Sell |
15,575
-55,200
| -78% | -$1.12M | ﹤0.01% | 7841 |
|
|
2018
Q3 | $2.83M | Buy |
70,775
+3,700
| +6% | +$105K | ﹤0.01% | 3443 |
|
|
2018
Q2 | $1.9M | Sell |
67,075
-2,675
| -4% | -$59.3K | ﹤0.01% | 4100 |
|
|
2018
Q1 | $1.07M | Buy |
69,750
+40,850
| +141% | +$973K | ﹤0.01% | 5102 |
|
|
2017
Q4 | $943K | Buy |
+28,900
| New | +$779K | ﹤0.01% | 5360 |
|
Susquehanna International Group's MRNS Position: Q1 2025 in Review
Susquehanna International Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 100,853 shares — an estimated $54K sold.
Susquehanna International Group first reported a position in MRNS in Q3 2016 and held it in 28 quarters. The position peaked at $4.05M in Q1 2021. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- Susquehanna International Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- Susquehanna International Group sold 100,853 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $54K.
- Susquehanna International Group first reported a position in Marinus Pharmaceuticals, Inc in Q3 2016 and held it in 28 quarters.
- Susquehanna International Group's Marinus Pharmaceuticals, Inc position peaked at $4.05M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.